SCHEMBL6092810

SCHEMBL6092810

COc1ccc(Br)c(OC)c1C(=O)Cc1c(Cl)cccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 10/20 0.47
KCNB1 Q14721 1/20 0.43
ALDH1A1 P00352 1/20 0.42
THRB P10828 1/20 0.41
AKR1B1 P15121 1/20 0.41
MC4R P32245 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092756 0.78 TTR (0.48) ALDH1A1
SCHEMBL6092674 0.78 ERN1 (0.44) PDE4DKCNB1ALDH1A1THRB
SCHEMBL6091647 0.77 LMNA (0.40) KCNB1ALDH1A1
SCHEMBL11521097 0.74 TSHR (0.44) ALDH1A1KCNH2
SCHEMBL5997647 0.73 MEN1 (0.42) ALDH1A1KCNH2
SCHEMBL6092876 0.73 MAPT (0.45) KCNH2
SCHEMBL6093551 0.72 PIK3CA (0.42)
SCHEMBL1323122 0.72 CA12 (0.55) ALDH1A1KCNH2
SCHEMBL4599128 0.72 MEN1 (0.47) ALDH1A1KCNH2
SCHEMBL12593466 0.72 CA9 (0.46) ALDH1A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 PDE4D 360/4885KCNB1 1427/4885ALDH1A1 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.